Fluorescein Angiography in Patients With Diabetes and Chronic Kidney Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Fluorescein angiography.
- Who it may be relevant to
- Registry conditions: Chronic Kidney Disease Stage 4, Chronic Kidney Disease Stage 3B, Chronic Kidney Disease Stage 5, Diabetes Mellitus. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Lebanon
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Fluorescein-Induced Acute Kidney Injury in Patients With Diabetes and Chronic Kidney Disease
Overview
Our study hypothesizes that fluorescein exposure in diabetic patients with advanced chronic kidney disease results in deterioration of kidney function. It will therefore aim to evaluate the incidence of acute kidney injury induced by fluorescein in diabetic patients with CKD. The objective is to determine the incidence, severity and risk factors associated with this deterioration to improve the care of this specific population.
Detailed description
This study will assess the change in serum creatinine in patients with diabetes and advanced chronic kidney disease, after a fluorescein angiography. This is a before and after study that will include 35 patients from the department of ophtalmology over 6 months with a total follow-up for 3 months.
Interventions
- Diagnostic test Fluorescein angiography
Fluorescein angiography
Primary outcome measures
- Change in serum creatinine [Time frame: At day 4]
Secondary outcome measures (1)
- Long-term change in serum creatinine [Time frame: 3 months]
Eligibility criteria
Inclusion criteria
- >18 years old with type 2 or type 1 diabetes and chronic kidney disease stage 3b to 5 (eGFR<45 mL/min/1.73 m2)
Exclusion criteria
- Patients who do not give their consent
- Patients who are allergic to fluorescein
- Patients who are on dialysis
- Patients who had fever, vomiting, diarrhea or any dehydration 48 hours before the intervention
- Patients who had a treatment modification one week before the intervention
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Diagnostic
Study locations
Lebanon · 1 center
- Faculty of Medicine, Saint Joseph University of Beirut — Beirut
Identifiers
NCT: NCT06760650 · CEHDF 2587 · Tfem-2025-79